

RESEARCH

Open Access



Inhibition of *Sesn2* has negative regulatory effects on the myogenic differentiation of C2C12 myoblasts

Zubiao Song¹, Qing Lin¹, Jiahui Liang¹ and Weixi Zhang^{1*}

Abstract

Sestrin2 (*Sesn2*) has been previously confirmed to be a stress-response molecule. However, the influence of *Sesn2* on myogenic differentiation remains elusive. This study was conducted to analyze the role of *Sesn2* in the myogenic differentiation of C2C12 myoblasts and related aspects in mdx mice, an animal model of Duchenne muscular dystrophy (DMD). Our results showed that knockdown of *Sesn2* reduced the myogenic differentiation capacity of C2C12 myoblasts. Predictive analysis from two databases suggested that miR-182-5p is a potential regulator of *Sesn2*. Further experimental validation revealed that overexpression of miR-182-5p decreased both the protein and mRNA levels of *Sesn2* and inhibited myogenesis of C2C12 myoblasts. These findings suggest that miR-182-5p negatively regulates myogenesis by repressing *Sesn2* expression. Extending to an in vivo model of DMD, knockdown of *Sesn2* led to decreased Myogenin (*Myog*) expression and increased Pax7 expression, while its overexpression upregulated *Myog* levels and enhanced the proportion of slow-switch myofibers. These findings indicate the crucial role of *Sesn2* in promoting myogenic differentiation and skeletal muscle regeneration, providing potential therapeutic targets for muscular dystrophy.

Keywords Sestrin2, miR-182-5p, Myogenic differentiation, Duchenne muscular dystrophy, Slow-twitch myofibers

Introduction

The sestrin (*Sesn*) family (*Sesn1*, 2, 3) is identified as a conventional group of stress-responsive proteins that modulate metabolism by monitoring nutrient levels and redox status in cells, tissues and organs [1]. Within this protein family, *Sesn2* has been shown to be associated with musculoskeletal disorders [2]. In denervated muscle atrophy, *Sesn2* acts to prevent the switch from slow-twitch to fast-twitch myofibers and maintains muscle mass through the AMPK/PGC-1 α pathway [3]. A study

in a dexamethasone-induced muscle atrophy model also demonstrated that *Sesn2* functions as a potential protective molecule by inhibiting the FoxO3a and MSTN/Smad pathways [4]. Thus, these compelling evidence have shown that *Sesn2* is essential for preventing skeletal muscle atrophy. Skeletal muscle atrophy is closely related to its regenerative capacity, but the role of *Sesn2* in the regeneration of skeletal muscle remains largely unknown.

Skeletal muscle inherently possesses a regenerative mechanism that maintains structural and functional stability when it is damaged by external factors or disease. Notably, satellite cells (SCs), located in the niche between the surface of the sarcolemma and the basal lamina [5], play a key role in this repair process by undergoing asymmetric division and myogenic differentiation [6]. Under quiescent conditions, SCs typically express the characteristic marker paired box 7 (*Pax7*), which is essential for maintaining the SCs pool and regulating

*Correspondence:

Weixi Zhang
zhangwx@mail.sysu.edu.cn

¹ Department of Neurology, The First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases; National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

their survival, proliferation, and differentiation [7, 8]. When skeletal muscle is damaged, SCs re-enter the cell cycle, proliferate and undergo myogenic differentiation to repair the damaged muscle region [9]. The impaired myogenic differentiation ability of SCs diminishes the regenerative capacity of skeletal muscles after injury, eventually causing skeletal muscle atrophy and related issues. Therefore, understanding the mechanism that influences the myogenesis of SCs would aid in promoting skeletal muscle regeneration. To conveniently uncover the factors regulating the myogenic differentiation, C2C12 myoblasts are commonly used as an in vitro model to recapitulate the differentiation process of SCs [10]. Despite numerous studies indicating that *Sesn2* regulates cellular processes such as lipid biosynthesis [11], inflammation [12], and insulin resistance [13] in C2C12 cells so far, its role in myogenic differentiation remains elusive and warrant further investigation.

After leaving the cell cycle, the C2C12 myoblasts enter the myogenic differentiation program, which is mainly governed by two categories of transcription factors [14, 15]: myogenic regulatory factors (MRFs, including MyoD, Myogenin (Myog), Myf5 and MRF4 [16, 17]) and myocyte enhancer factor 2 (MEF2). MRFs, as a member of the basic helix-loop-helix (bHLH) transcription factor family, combine with E proteins such as E12 to promote the transcription of skeletal muscle-specific genes by binding to the E-box (CANNTG) within their regulatory regions [18]. Myf5 and MyoD are essential for myogenic determination [19], whereas Myog shares a structural similarity with MyoD and plays a crucial role in terminal differentiation [17, 20]. Previously, researchers inferred that *Sesn2* could regulate the myogenesis of C2C12 myoblasts by controlling mitochondrial quality under stress conditions induced by reactive oxygen species (ROS), but no direct studies have confirmed this involvement [21]. Additionally, it remains unclear whether *Sesn2* is regulated by other factors during the differentiation of C2C12 myoblasts.

Recent studies [22, 23] have shown that microRNAs (miRNAs) can regulate the myogenic differentiation of C2C12 cells by modulating the activity of target genes. MiRNAs, non-coding RNAs of approximately 22nt, bind to complementary sequences within the 3'UTR of target genes, leading to either degeneration of the target mRNA or the suppression of its translation [24]. For instance, miR-696 inhibits C2C12 myoblasts myogenesis by repressing CNTFR α expression [22], while miR-204-5p inhibits myogenic differentiation of C2C12 myoblasts and the formation of slow-twitch myofibers by targeting MEF2C and ERR γ [23]. Therefore, understanding the regulatory mechanism of miRNAs not only elucidates the molecular basis underlying myoblasts differentiation but

also provides new strategies for the treatment of muscular diseases.

Duchenne muscular dystrophy (DMD) is a lethal neuromuscular disorder caused by mutations in the *DMD* gene located on the X chromosome [25]. These mutations result in the loss of dystrophin, which is a component of the dystrophin-associated protein complex (DAPC) [25]. Since dystrophin is crucial for maintaining the integrity of the sarcolemma, its absence results in pathological manifestations, including myofibrillar degeneration, inflammatory infiltration and fibrosis in skeletal muscle [25].

In this study, we first investigated the effects of *Sesn2* on the myogenic differentiation of C2C12 myoblasts. Additionally, we employed databases to predict miRNAs that could interact with *Sesn2* mRNA and validated this regulatory relationship. Furthermore, we examined the impact of *Sesn2* on the regeneration degree and the proportion of slow-twitch myofibers in skeletal muscle in DMD model mice (mdx mice). This study clarified the basis by which *Sesn2* and related miRNA regulate myogenic differentiation, providing new targets for the treatment of muscular disorders such as DMD.

Results

***Sesn2* is involved in the myogenic differentiation of C2C12 myoblasts**

To validate the effects of *Sesn2* on myogenic differentiation, we first aimed to observe the expression trend of *Sesn2* over the extended differentiation period of C2C12 myoblasts. On day 0 (the undifferentiated state), C2C12 myoblasts exhibited a spindle-shaped morphology (Fig. 1a). As differentiation progressed, the cells underwent a gradual morphological transformation, manifesting as the formation of distinctive elongated myotube structures indicative of successful differentiation (Fig. 1a). The expression of the Myog and Myh6 gradually increased with prolonged differentiation (Figs. 1b, S1a and S1b), further confirming differentiation toward myotube formation. *Sesn2* protein expression was significantly decreased 1 day after differentiation induction (Figs. 1b and S1c). However, after 3 days of differentiation, *Sesn2* expression was markedly increased compared to that on the first day, although it remained significantly lower than that in the undifferentiated cells (Day 0) (Figs. 1b and S1c).

Next, C2C12 myoblasts were divided into two groups: the si*Sesn2* group (transfected with *Sesn2*-specific siRNA) and the siNC group (transfected with siNC). After 12 h of transfection, the cells were induced to differentiate for 3 days. Western blotting (WB) analysis confirmed that the relative expression level of *Sesn2* was significantly lower in the si*Sesn2* group than in the siNC




Fig. 1 Effect of Sesn2 on the myogenic differentiation of C2C12 myoblasts. **a** Changes in cellular morphology. With increasing differentiation time, the cells gradually adopted a spindle-shaped myotube morphology. Scale bar = 200µm. **b** Temporal expression trends of myogenic differentiation markers and Sesn2. Myh6 and Myog expression gradually increased with prolongation of differentiation. However, the Sesn2 protein level significantly decreased 1 day after induction and then increased on the third day. The expression levels on days 1 and 3 were significantly lower than those in undifferentiated cells. **c, d** Determination of myogenic differentiation ability after Sesn2 knockdown. WB analysis revealed significant decreases in the expression of Myh6, Sesn2, Myh4 and Myog in the siSesn2 group. **e f** IF analysis of the fusion index of MHC-positive myotubes. The fusion index was significantly lower in the siSesn2 group than in the siNC group. Scale bar = 100µm. Student's t test. The data are displayed as the mean ± standard deviation. *n* = 5–6. ****p* < 0.001

group (0.58 ± 0.10 vs. 0.96 ± 0.15 , $p < 0.001$; Figs. 1c and S1e). Subsequent comparison revealed that the relative expression of Myog in the siSesn2 group was significantly decreased by 27.93% compared with that in the siNC group (0.80 ± 0.13 vs. 1.11 ± 0.29 , $p < 0.05$; Figs. 1d and S1f). Additionally, the relative expression of Myh6 in the siSesn2 group was 41.54% lower than that in the siNC group (0.38 ± 0.10 vs. 0.65 ± 0.13 , $p < 0.01$; Figs. 1c and S1d), and the relative expression of Myh4 in the siSesn2

group was also lower than that in the siNC group (0.27 ± 0.18 vs. 0.66 ± 0.21 , $p < 0.01$; Figs. 1d and S1g). Further immunofluorescence (IF) analysis of MHC expression revealed a significantly lower fusion index in MHC-positive myotubes in the siSesn2 group than in the siNC group ($p < 0.001$; Fig. 1e and f). These findings further confirm the involvement of Sesn2 in the myogenic differentiation of C2C12 myoblasts, and suggest that inhibiting Sesn2 expression reduced the myogenic capability.

Predictive identification of miR-182-5p as a potential regulator of *Sesn2*

Subsequently, we aimed to further study the upstream regulatory mechanisms of *Sesn2* during myogenesis. Given the regulatory role of miRNAs in governing gene translation and their potential impact on C2C12 myoblast differentiation [26], we utilized databases to predict miRNAs capable of binding to *Sesn2*. As shown in Fig. 2a, 46 miRNAs capable of binding to *Sesn2* were predicted by the miRDB, while two sets of predictions, namely, a conserved set (containing 13 miRNAs) and a poorly conserved set (containing 426 miRNAs), were obtained via TargetScan. The intersection of the sets of predictions from both databases revealed 4 miRNAs with the potential to bind to *Sesn2* (Fig. 2a). Importantly, complementary binding sites for miR-182-5p were found within a segment of the *Sesn2* 3'UTR (Fig. 2b). The potential interaction between miR-182-5p and *Sesn2* was then investigated further. As the differentiation time increased, the miR-182-5p level initially increased and then decreased (Fig. 2c). Similar to the protein expression trend mentioned above (Figs. 1b and S1c), *Sesn2* mRNA expression decreased on the first day of differentiation and significantly increased on the third day (Fig. 2d). The trends in *Sesn2* and miR-182-5p expression were opposite, indicating the possibility that these two factors interact.

***Sesn2* is regulated by miR-182-5p**

Next, to further confirm the relationship between miR-182-5p and *Sesn2*, C2C12 myoblasts were divided into two groups: the Mimic-182-5p group (transfected with the miRNA-182-5p mimic) and the Mimic-NC group (transfected with the negative control miRNA). Following transfection, the cells were induced to differentiate for 3 days and were then harvested for subsequent assessment. RT-qPCR revealed that the relative expression level of miR-182-5p in the Mimic-182-5p group was increased by approximately 1008-fold compared with that in the Mimic-NC group ($p < 0.0001$, Fig. 3a), indicating that miR-182-5p was successfully overexpressed in the Mimic-182-5p group. However, the mRNA level of *Sesn2* in the Mimic-182-5p group decreased by 24.45% compared with that in the Mimic-NC group ($p < 0.0001$, Fig. 3b). Additionally, compared with those in the Mimic-NC group, the *MyoD* and *Myog* mRNA levels in the Mimic-182-5p group were significantly decreased, by 58.63% ($p < 0.0001$, Fig. 3c) and 61.60% ($p < 0.0001$, Fig. 3d), respectively. In further validation of these results, protein expression analysis confirmed that the *Sesn2* protein level was significantly lower in the Mimic-182-5p group than in the Mimic-NC group (0.78 ± 0.06 vs. 1.07 ± 0.13 , $p < 0.001$; Figs. 3e and S1h). The protein expression levels of *Myh6* and *Myog* in the Mimic-182-5p group were also significantly lower than those in the Mimic-NC group, by 64.28% ($p < 0.001$, Figs. 3e and S1i) and 57.84% ($p < 0.0001$, Figs. 3e and S1j), respectively.





Fig. 2 miR-182-5p was identified as a potential regulator of *Sesn2*. **a** Prediction of miRNAs. Based on the predictions from two databases (TargetScan and miRDB), 4 miRNAs were identified as potentially interacting with *Sesn2* through complementary base pairing. **b** Schematic diagram showing the binding of miRNA-182-5p to the *Sesn2* 3'UTR. **c**, **d** After prolonged induction of differentiation in C2C12 myoblasts, the trends in the expression of miRNA-182-5p and *Sesn2* were examined. One-way ANOVA test. $n = 6$. The data are displayed as the mean \pm standard deviation. ns $p > 0.05$, *** $p < 0.001$, **** $p < 0.0001$



These results indicate that overexpressing miR-182-5p in C2C12 myoblasts can effectively inhibit *Sesn2* expression and myogenesis.

We also constructed two vectors based on the pmirGLO vector: pmirGLO-*Sesn2*-3'UTR-Wt and pmirGLO-*Sesn2*-3'UTR-Mut, encoding the wild-type and mutant versions, respectively, of the *Sesn2* 3'UTR sequence containing the miRNA-182-5p binding site (Fig. 3h).

These vectors were cotransfected with Mimic-182-5p or Mimic-NC into HEK293T cells. Luciferase activity was significantly lower in the pmirGLO-*Sesn2*-3'UTR-Wt + Mimic-182-5p group than in the pmirGLO-*Sesn2*-3'UTR-Wt + Mimic-NC group (Fig. 3f). Moreover, luciferase activity did not differ significantly between the pmirGLO-*Sesn2*-3'UTR-Mut + Mimic-182-5p and pmirGLO-*Sesn2*-3'UTR-Mut + Mimic-NC groups (Fig. 3g).

These results strongly support the hypothesis that miRNA-182-5p binds to *Sesn2* mRNA.

Sesn2 is upregulated in the skeletal muscle of mdx mice

Above results revealed that inhibition of *Sesn2* suppressed myogenic differentiation of C2C12 myoblasts, suggesting a potential role for *Sesn2* in skeletal muscle regeneration. To further verify the biological function of *Sesn2*, we selected mdx mice for further in-depth study. The mdx mouse is a classic animal model for DMD characterized by the coexistence of necrosis and regeneration processes in its skeletal muscles. Comparing to those in C57BL/10 J mice (control group), hematoxylin and eosin staining (H&E) staining revealed significant inflammatory cell infiltration in the tibialis anterior muscle (TA) and diaphragm muscles (DIA) in the mdx mice (DMD group), along with a considerable number of centrally nucleated myofibers (Fig. 4a and b). Inflammatory cell infiltration was more pronounced in the DIA of mdx mice (Fig. 4b). Some myofibers even contained multiple centrally localized nuclei. These phenomena indicate the occurrence of damage and self-repair processes in skeletal muscle in the DMD model. Additionally, IF staining of the gastrocnemius muscle (GAS) revealed the presence of dystrophin on the sarcolemma in the control group (Fig. 4c). In comparison, the DMD group exhibited a marked reduction in the fluorescence signal of dystrophin, approaching 0% ($p < 0.01$, Fig. 4c and d). This finding suggested the absence of the dystrophin protein on the sarcolemma in the DMD group, consistent with the genetic and molecular characteristics of DMD.

Next, we examined *Sesn2* expression in the skeletal muscle of the DMD group compared with the control group. WB analysis revealed significant upregulation of *Sesn2* in the TA, DIA and GAS of the DMD group compared to the control group (Figs. 4e and S2a-S2c). In the GAS, *Sesn2* expression in the DMD group was increased by 84.85% compared with that in the control group (0.61 ± 0.18 vs. 0.33 ± 0.19 , $p < 0.05$; Fig. S2a). In the TA, the relative expression level of *Sesn2* in the DMD group was increased by 72.09% compared with that in the control group (0.74 ± 0.09 vs. 0.43 ± 0.11 , $p < 0.01$; Figs. 4e and S2c). DIA revealed that the relative expression level

of *Sesn2* in the DMD group was 54.55% greater than that in the control group (0.68 ± 0.07 vs. 0.44 ± 0.14 , $p < 0.05$; Fig. S2b). Furthermore, considering the degrees of fibrosis and inflammation reported in the literature [27], the DIA was found to be the most severely affected, followed by the TA and the soleus muscle (SOL). WB analysis revealed that *Sesn2* expression was greater in the DIA than those in either the TA or the SOL (Figs. 4f and S2d). These findings suggested that *Sesn2* expression is elevated in the regions with the most severe damage. Subsequent IF analysis of the distribution and relative expression of *Sesn2* further confirmed the significant increase in *Sesn2* protein levels in the DMD group (Fig. 4g and h), indicating a potential association between *Sesn2* and disease progression in mdx mice.

Sesn2 is associated with the degree of skeletal muscle regeneration in mdx mice

Given the notable upregulation of *Sesn2* in the skeletal muscle of mdx mice, we sought to further study the impact of *Sesn2* on mdx mouse skeletal muscle by establishing models of *Sesn2* overexpression or knockdown. The mdx mice were divided into 3 groups. At 4 weeks of age, the mice received an intravenous (tail vein) injection of AAV to induce *Sesn2* overexpression (3xFlag-*Sesn2* group) or knockdown (sh*Sesn2* group) in skeletal muscle. The control group of mdx mice (DMD group) was administered an equivalent volume of PBS. Tissue samples were harvested one month postinjection for subsequent experiments (Fig. 5a). The expression of *Sesn2* was validated by WB analysis. In the TA, *Sesn2* expression was decreased by 50.68% in the sh*Sesn2* group compared with that in the DMD group ($p < 0.05$, Fig. S3a and S3b), while in the GAS, *Sesn2* expression was decreased by 45.45% ($p < 0.05$, Fig. S3c and S3d). Conversely, the relative expression level of *Sesn2* in the 3xFlag-*Sesn2* group was significantly greater than that in the DMD group in both the TA (0.80 ± 0.06 vs. 0.02 ± 0.01 , $p < 0.0001$; Fig. S3e and S3f) and GAS (0.84 ± 0.25 vs. 0.02 ± 0.01 , $p < 0.05$; Fig. S3g and S3h). These results validated the successful overexpression and knockdown of *Sesn2*.

Then, we focused on the influence of *Sesn2* overexpression and knockdown on skeletal muscle regeneration in

(See figure on next page.)

Fig. 4 Comparison of *Sesn2* expression between the mdx mice and C57BL/10 J mice. **a** H&E staining of the tibialis anterior muscle (TA). Left side, control group; right side, DMD group. Scale bar = 200 μ m. **b** H&E staining of the diaphragm muscle (DIA). Left side, control group; right side, DMD group. Scale bar = 200 μ m. **c, d** IF analysis of dystrophin in the gastrocnemius muscle (GAS). Clear dystrophin fluorescence was observed in the control group, while the signal was minimal in the DMD group. Scale bar = 100 μ m. $n = 5$. Student's t test. **e** Protein expression analysis of *Sesn2* in the TA. *Sesn2* was significantly upregulated in the DMD group. **f** Comparison of *Sesn2* protein levels in the TA, SOL and DIA of mdx mice. The highest expression level was detected in the DIA. **g, h** IF detection of *Sesn2* levels and distribution in the TA. A notable increase in expression was observed in the DMD group. Scale bar = 200 μ m. Student's t test. The data are displayed as the mean \pm standard deviation. $n = 5$. Student's t test. * $p < 0.05$, ** $p < 0.01$




Fig. 4 (See legend on previous page.)




Fig. 5 Influence of Sesn2 on the expression of myogenic regulatory factors in the skeletal muscles of mdx mice. **a** Schematic diagram of the mouse modeling process. Four-week-old mdx mice were divided into three groups: the overexpression group (3xFlag-Sesn2 group), in which the mice were administered AAV (AAV2/9-CMV-3xflag-Sesn2-ZsGreen) overexpressing Sesn2; the knockdown group (shSesn2 group), in which the mice were administered AAV2/9-U6-Sesn2-shRNA-EGFP targeting Sesn2 for knockdown; and the control group (DMD group), in which the mice were administered an equivalent volume of PBS. All treatments were administered via tail vein injection. Tissues were collected one month postinjection for subsequent experimental assessments. **b** Protein levels of Myog and Pax7 in the GAS. There were significant decreases in the protein expression levels of Myog in the shSesn2 group. Pax7 expression was significantly increased in the shSesn2 group. **c** Protein levels of Myog in the GAS. In the 3xFlag-Sesn2 group, Myog expression was significantly upregulated

mdx mice. Given that the compromised myogenic differentiation contributes to impaired skeletal muscle regeneration in DMD, we investigated the changes in the expression of myogenic regulatory factors (MRFs). Compared with the DMD group, the shSesn2 group exhibited a 63.93% decrease in Myog expression in the TA (0.22 ± 0.10 vs. 0.61 ± 0.23 , $p < 0.05$; Fig. S3i and S3j). In the GAS, Myog expression in the shSesn2 group was also significantly lower than that in the control group (0.38 ± 0.09 vs. 0.79 ± 0.20 , $p < 0.05$; Figs. 5b and S3o). Compared with that in the DMD group, the expression of desmin in the GAS was decreased by 57.69% in the shSesn2 group (0.33 ± 0.08 vs. 0.78 ± 0.18 , $p < 0.01$; Fig. S3k and S3l). However, examination of Pax7 (a marker of satellite cells) in the GAS revealed that the expression level in the shSesn2 group was significantly greater than that in the DMD group (0.85 ± 0.27 vs. 0.29 ± 0.06 , $p < 0.01$; Figs. 5b and S3q). Conversely, in the TA, the relative expression level of Myog in the 3xFlag-Sesn2 group was increased by

1.41-fold compared with that in the DMD group (1.81 ± 0.19 vs. 0.75 ± 0.36 , $p < 0.01$; Fig. S3m and S3n). Furthermore, in the GAS, the relative expression levels of Myog (1.34 ± 0.17 vs. 0.86 ± 0.11 , $p < 0.01$) in the 3xFlag-Sesn2 group were significantly increased compared with those in the DMD group (Figs. 5c and S3p). Thus, the findings of the present study suggested that Sesn2 is involved in the process of skeletal muscle regeneration in mdx mice.

Overexpression of Sesn2 elevates the proportion of slow-twitch myofibers in the skeletal muscle of mdx mice

Given the above findings indicating that the modulation of Sesn2 expression can influence the expression of Myh6 (a slow-twitch myofiber marker), and the preliminary evidence suggesting the effect of Sesn2 on the slow-to-fast myofiber transition [3], we next explored the impact of Sesn2 on the myofiber type in mdx mice. WB analysis revealed a significant increase in the relative protein level

of the fast-twitch myofiber marker Myh2 in the shSesn2 group compared to the DMD group (0.51 ± 0.33 vs. 0.09 ± 0.06 , $p < 0.05$; Figs. 6a and S4a). In the 3xFlag-Sesn2 group, overexpression of Sesn2 resulted in a significant increase in the protein expression levels of slow-twitch myofiber markers. Specifically, the expression of Myh6 in the GAS and TA was increased by approximately 2.4-fold ($p < 0.05$, Figs. 6b and S4b) and 1.83-fold ($p < 0.05$, Figs. 6c and S4c), respectively, in the 3xFlag-Sesn2 group. Notably, the relative protein expression of myoglobin in the 3xFlag-Sesn2 group was increased by 63.33% compared with that in the DMD group ($p < 0.01$, Figs. 6c and S4d). Moreover, IF analysis revealed a substantial increase in the proportion of slow MHC-positive myofibers in the TA following Sesn2 overexpression ($p < 0.01$, Fig. 6d and e). These data indicate that Sesn2 influences the myofiber type transition in mdx mice; specifically, Sesn2 overexpression increases the proportion of slow-twitch myofibers.

Discussion

Findings from earlier studies suggested a connection between Sesn2 and skeletal muscle atrophy [3], which is a pathological condition related to the regenerative capacity. Specifically, the impaired myogenic differentiation capacity of SCs results in diminished regenerative capacity [28]. Therefore, understanding the factors governing myogenic differentiation is significant for developing therapies for muscular disorders.

A previous review [21] has inferred that Sesn2 could regulate myogenic differentiation of C2C12 myoblasts by affecting mitophagy, but there is currently no direct evidence to confirm this relationship. To investigate the influence of Sesn2, we first examined the expression trend of Sesn2 over the course of C2C12 myoblasts differentiation. The results indicated that both the protein and mRNA expression levels first decreased and then increased. Earlier study [29] have shown that the mRNA expression level of Sesn2 decreases after




Fig. 6 Effect of Sesn2 on the proportion of slow-twitch myofibers in the skeletal muscle of mdx mice. **a** Impact of Sesn2 knockdown on Myh2 expression in the TA. In the shSesn2 group, a pronounced increase in Myh2 expression was observed in the TA. **b** Upregulation of Myh6 in the GAS following Sesn2 overexpression. **c** Increased Myh6 and myoglobin levels in the TA of mice in the 3xFlag-Sesn2 group. **d, e** Increased proportion of slow MHC-positive myofibers in the 3xFlag-Sesn2 group. Student's t test. Scale bar = 100µm. The data are displayed as the mean \pm standard deviation. $n = 4-5$. * $p < 0.05$, ** $p < 0.01$

3 days of C2C12 myoblasts differentiation, but they did not conduct further analysis at the protein expression level. The initial decrease in expression during the early stages of differentiation may be a component of the regulatory mechanism that primes the cells for differentiation. The subsequent gradual increase in the *Sesn2* expression as differentiation advances suggests that elevated levels of *Sesn2* are necessary for the later phases of myogenic differentiation, such as myotube formation. Moreover, further validation revealed that knocking down the expression of *Sesn2* leads to a reduced differentiation capacity of C2C12 myoblasts, as evidenced by impaired myotube formation and reduced levels of MRFs such as *Myog*. These results strongly indicate that the *Sesn2* is essential for proper myoblasts differentiation into myotubes, which aligns with previous hypothesis [21]. However, we did not investigate changes in autophagy or mitophagy. This represents a limitation of our current research. More studies should aim to elucidate the role of autophagy and mitophagy in this context by measuring changes in autophagic and mitophagic activity following the inhibition of *Sesn2*. For instance, it is necessary to assess the levels of key autophagy markers such as LC3B and p62 [30] at first.

Earlier studies [22, 23] indicated that miRNAs could influence the myogenic differentiation of C2C12 myoblasts. In this study, we performed bioinformatic analysis to identify 4 potential miRNAs which may regulate the activity of *Sesn2*. A previous study [26] have confirmed that miR-122-5p can reverse the inhibition of myogenic differentiation in C2C12 cells induced by TGF- β . However, we found that the overexpression of miR-122-5p did not result in any change in the expression of *Sesn2* (data not shown). This findings suggested that *Sesn2* is likely not regulated by miR-122-5p during the differentiation of C2C12 myoblasts. Next, we analyzed the changes in the expression of miR-182-5p. RT-qPCR analysis revealed that the changes in the mRNA expression of miR-182-5p was opposite to that of *Sesn2*. Considering the mechanism by which miRNAs bind to target mRNAs to cause degradation or translation inhibition [24], these results suggested a potential interaction between them. Further validation revealed that overexpression of miR-182-5p in C2C12 myoblasts led to a significant decrease in both the protein and mRNA expression levels of *Sesn2*, concomitant with impaired myogenic differentiation. This inhibitory effect of miR-182-5p on *Sesn2* expression and subsequent myogenesis highlights the significance of this miRNA-mediated regulatory axis in governing the myogenic program. This study could pave the way for developing targeted therapeutic strategies by regulating the miR-182-5p-*Sesn2* axis to promote the function of SCs and improve

regeneration in the context of muscular dystrophy, such as DMD.

To substantiate these in vitro findings, we investigated the role of *Sesn2* in the skeletal muscle of a mdx mouse model of DMD. H&E staining revealed that centrally nucleated myofibers and inflammatory cells infiltration coexisted in the skeletal muscle of mdx mice. These results highlight the ongoing cycles of muscle degeneration and regeneration, which are consistent with previous studies [31]. As regeneration is closely associated with myogenic differentiation of SCs, the mdx mouse is suitable for investigating the role of *Sesn2* on regenerative capacity of skeletal muscle. Our further findings, obtained from WB and IF analysis, demonstrated an upregulation of *Sesn2* in the skeletal muscles of mdx mice. This observation is similar to that of an earlier study [3] that reported an increased expression of *Sesn2* in a denervated muscle atrophy model. Inspired by the results of a previous study [3], upregulation of *Sesn2* may play a protective role in promoting regeneration of the skeletal muscles of mdx mice.

To verify this hypothesis, we generated the *Sesn2*-overexpression and *Sesn2*-knockdown mdx mice. Subsequent protein analysis revealed that knockdown of *Sesn2* in the skeletal muscle of mdx mice resulted in decreased expression of *Myog*, a key MRF for terminal differentiation of SCs [32], and increased expression of *Pax7*, a marker for quiescent SCs [7, 8]. Conversely, overexpression of *Sesn2* led to an increase in *Myog* expression levels. This findings suggested that *Sesn2* positively regulates myogenesis by promoting the expression of *Myog*, thereby driving myoblasts myogenic differentiation and increasing the regenerative degree of regeneration. Upregulation of *Pax7* expression following *Sesn2* knockdown may indicate a shift toward maintaining a more quiescent state, potentially hindering effective muscle regeneration. In contrast, the upregulation of *Myog* upon *Sesn2* overexpression supports the notion that *Sesn2* facilitates myogenic differentiation, aiding in regeneration. However, this study did not directly test the expression of embryonic myosin heavy chain (eMyHC), which is related to newly formed myofibers during regeneration [33]. Collectively, these findings suggest that *Sesn2* plays a pivotal role in regulating the myogenic program in mdx mice.

Early experiments [3] confirmed that knocking down *Sesn2* in a denervation-induced atrophy model accelerates the progression of skeletal muscle atrophy and is induced by the conversion of slow-twitch to fast-twitch myofibers. In our study on C2C12 myoblasts, after *Sesn2* expression was knocked down, the *Myh6* expression level decreased significantly. Moreover, our study showed that *Sesn2* knockdown in the mdx mice resulted in significantly increased expression of fast-twitch myosin heavy

chain 2 (Myh2 [34]), while *Sesn2* overexpression led to significantly elevated levels of the slow-twitch myofiber markers Myh6 [35] and Myoglobin [3] and an increased proportion of slow-twitch myofibers. These findings parallel those of previous research [3] suggesting the important role of *Sesn2* in elevating the proportion of slow-twitch myofibers. Considering the crucial role of slow-twitch myofibers in fatigue resistance and exercise endurance, previous literature [36] has indicated that increasing the number of slow-twitch myofibers could be a therapeutic strategy for attenuating DMD phenotypes. Our findings suggest that interventions targeting *Sesn2* could increase the proportion of slow-twitch myofibers in mdx mice. However, this study is a preliminary study on the effect of *Sesn2* on slow-twitch myofibers in the skeletal muscle of mdx mice, and the specific mechanism through which *Sesn2* causes this elevation in this model is worthy of further study.

In summary, our research revealed *Sesn2* as a novel regulator of myogenic differentiation that acts downstream of miR-182-5p. *Sesn2* overexpression increases the proportion of slow-twitch myofibers and increased the degree of regeneration in the skeletal muscle of mdx mice. These findings provide a potential therapeutic target for enhancing the regenerative capacity of skeletal muscle and alleviating muscular wasting conditions associated with impaired myogenesis.

Materials and methods

Recombinant Adeno-associated Virus (AAV)

To achieve *Sesn2* overexpression or knockdown in mouse skeletal muscle, AAVs were generated. AAV2/9-CMV-*Sesn2*-3xflag-ZsGreen (titer: 1.5×10^{12} vg/ml) was engineered to selectively overexpress *Sesn2*, and AAV2/9-U6-*Sesn2*-shRNA-EGFP (titer: 1.2×10^{12} vg/ml) was developed to specifically express the shRNA sequence for *Sesn2* knockdown. The *Sesn2* shRNA sequence in AAV2/9-U6-*Sesn2*-shRNA-EGFP was 5'-GCAUCAGAUACGAUGACUA-3'. Both viruses were produced by Hanbio (Shanghai, China).

Animals

Male C57BL/10 J mice and DMD model mice (mdx mice; C57BL/10ScSnJGpt-Dmd em3Cd4/Gpt) were purchased from GemPharmatech Biotechnology. Four-week-old male mdx mice were divided into three groups: the mdx mice + AAV2/9-CMV-*Sesn2*-3xflag-ZsGreen group (3xFlag-*Sesn2* group), the mdx mice + AAV2/9-U6-*Sesn2*-shRNA-EGFP group (sh*Sesn2* group) and the mdx mice + PBS group (DMD group). Each mdx mouse received an injection of 120 μ l AAV, and observations and assessments were conducted one month post-injection. The experimental mice were housed in controlled

environments, with a 12-h light/dark cycle, a temperature of 22 °C, and 50–60% humidity. The animals were provided free access to both bacteria-free water and standard laboratory food. The protocols for animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University (SYSU-IACUC-2023–001741).

Cell culture

C2C12 myoblasts cells were obtained from the Cell Bank of the Chinese Academy of Sciences. For proliferation and passaging, C2C12 myoblasts were cultured in growth medium (GM) comprising Dulbecco's modified Eagle's medium (DMEM; Gibco, C11995500BT) supplemented with 10% fetal bovine serum (FBS; Gibco, 10,091–148) in a humidified atmosphere with 5% CO₂ at 37 °C. To induce C2C12 myoblast differentiation, the GM was replaced with differentiation medium (DM) consisting of DMEM and 2% horse serum (HS; Gibco, 26,050,088).

Cell transfection

To investigate the role of *Sesn2* in C2C12 myoblast differentiation, cells were transfected with a specific siRNA to knock down *Sesn2* using Lipofectamine 3000 (Lipo3000; Gibco, L3000015) according to the manufacturer's instructions. Before transfection, the cells were seeded in a 6-well plate and allowed to grow to 70–80% confluence.

First, the siRNA and Lipo3000 were solubilized in two EP tubes, each containing 125 μ l Opti-MEM. Then, the diluted siRNA was transferred to an EP tube containing Lipo3000 and incubated for 15 min at room temperature. Finally, the siRNA and Lipo3000 complexes were added to each well and incubated for 12 h. The transfected cells were then used in experiments. The miR-182-5p mimic transfection procedure was similar to the siRNA transfection procedure detailed above. The *Sesn2* siRNA sense sequence was 5'-GCAUCAGAUACGAUGACUA-3', and the miR-182-5p mimic sequence was 5'-UUUGGCAAUGGUAGAACUCACACCG-3'. The siRNA, negative control siRNA (siNC), miR-182-5p mimic (Mimic-182-5p) and miRNA mimic negative control (Mimic-NC) were synthesized by and obtained from Tsingke Biological Technology (Beijing, China).

For plasmid transfection, 2 μ g of plasmid was mixed with 4 μ l of P3000 (provided in the kit) in an EP tube, to which Lipo3000 was then added. After incubation for 15 min, the mixture was added to the medium.

RNA extraction and real-time quantitative polymerase chain reaction (RT-qPCR)

In accordance with the manufacturer's instructions, AG RNAex Pro Reagent (Accurate Biotechnology, AG21102) was used to extract total RNA from cells. The RNA quality and concentration were determined by a NanoDrop2000 spectrophotometer (Thermo Scientific). Then, 1 µg of total RNA was reverse transcribed into cDNA using an Evo M-MLV RT Reaction Mix Kit (Accurate Biotechnology, AG11728). For miRNA analysis, 0.5 µg total RNA was reverse transcribed using an Evo M-MLV RT Kit for qPCR (Accurate Biotechnology, AG11707). RT-qPCR was performed using a SYBR Green Premix Pro Taq HS qPCR Kit (Accurate Biotechnology, AG11719) according to the manufacturer's instructions. The internal controls were GAPDH (for mRNA) and U6 (for miRNA). The primer sequences are provided in supplementary Table S1.

Western Blot (WB) analysis

Total protein was extracted from the cells or skeletal muscle samples by lysis in RIPA buffer (Thermo Scientific, 89,900) containing 1 mM PMSF (Beyotime, ST506) and PhosSTOP (Roche, 4,906,845,001). The protein concentration in each sample was detected with a Pierce BCA assay kit (Thermo Scientific, 23,227) following the manufacturer's instructions. Then, 10% or 12.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate equal amounts of proteins. After separation, the proteins were transferred to 6.5 × 7 or 8.5 × 7 mm PVDF membranes (Millipore), which were then blocked with 5% BSA in TBST (500 mM NaCl, 20 mM Tris-HCl, 0.2% Tween) for 1 h and incubated overnight at 4 °C with primary antibodies against the following proteins: Myoglobin (Abcam, ab77232), Myh2 (Abcam, ab124937), Myh4 (Proteintech, 20,140-1-AP), Myh6 (Abcam, ab185967), Sesn2 (Abcam, ab178518), Myog (Abcam, ab124800), Desmin (Abcam, ab32362), Pax7 (DSHB). Finally, the membranes were incubated for 1 h with HRP-conjugated anti-rabbit IgG antibodies (CST, 7074S) or HRP-conjugated anti-mouse IgG antibodies (CST, 7076S). The proteins were visualized with a chemiluminescence detection system. GAPDH (CST, 2118S) or β-tubulin (CST, 2128S) was used as the internal reference.

Immunofluorescence (IF) assay

IF assay was conducted to evaluate the effect of Sesn2 on C2C12 myoblast differentiation. First, the cells were washed twice with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde (PFA) for 20 min at room temperature. Then, the cells were blocked for 30 min with QuickBlock™ Blocking Buffer for Immunol

Staining (Beyotime, P0260) and then incubated with primary antibody at 4 °C overnight. For IF analysis of skeletal muscle, frozen samples were sectioned at a 10 µm thickness, fixed with acetone for 10 min, and washed twice with PBS for 10 min each. Then, the samples were blocked with goat serum for 1 h prior to overnight incubation with primary antibodies against the following proteins: myosin heavy chain, sarcomere (MHC) antibody (DSHB, MF20), dystrophin (Abcam, ab275391), Sesn2 (Proteintech, 10,795-1-AP), laminin (Sigma, L9393 or L8271), and slow MHC (Sigma, M8421). Next, the cells or frozen skeletal muscle sections were washed three times with PBS, and were then incubated with suitable secondary antibodies, including anti-rabbit Alexa Fluor 488-conjugated (CST, 4412S), anti-rabbit Alexa Fluor 555-conjugated (CST, 4413S), anti-rabbit Alexa Fluor 647-conjugated (CST, 4414S), anti-mouse Alexa Fluor 488-conjugated (CST, 4408S), anti-rabbit mouse Fluor 555-conjugated (CST, 4409S) and anti-mouse Alexa Fluor 647-conjugated (CST, 4410S) secondary antibodies. Next, the cells were washed 3 times with PBS and stained with DAPI (Sigma, F6057) to visualize the nuclei. Finally, the cells were observed and photographed under a fluorescence microscope. Multinucleated myotubes were defined as MHC-positive cells with two or more nuclei. The fusion index was calculated by dividing the number of nuclei in each multinucleated myotube by the total number of nuclei.

Prediction of target miRNAs

To investigate the potential upstream miRNAs regulating Sesn2, the TargetScan and miRDB databases were utilized to predict miRNAs capable of binding to Sesn2. Subsequently, the sets of predicted miRNAs obtained from each database were intersected to narrow the list of target miRNAs.

Dual-Luciferase reporter assay

To investigate the interaction between Sesn2 and miR-182-5p, the miR-182-5p binding site within the 3'UTR of Sesn2 mRNA, as well as a sequence containing a mutated binding site, was cloned and inserted into the pmirGLO Dual-Luciferase miRNA target expression vector (pmirGLO vector). Two reporter vectors were constructed by Tsingke Biological Technology (Beijing, China): the wild-type reporter vector (pmirGLO-Sesn2-3'UTR-Wt) and the mutant reporter vector (pmirGLO-Sesn2-3'UTR-Mut). HEK-293 T cells were co-transfected with either miR-182-5p mimic or mimic-NC, along with the above reporter vectors, using Lipo3000 as the transfection reagent. After 24-48 h of incubation, luciferase activity was determined utilizing a dual-luciferase reporter assay kit (Promega, E1910).

Hematoxylin and Eosin staining (H&E staining)

Frozen sections were hydrated by two immersions for 3 min each and were then stained with hematoxylin (Baso, BA4021A) for 2 min. The sections were rinsed twice with water for 3 min each, stained for 1 min with eosin (Beyotime, C0109), and rinsed twice more with water for 3 min each. The sections were dehydrated in an alcohol series (75%, 85%, 95%, 100%, and 100% again). The sections were then immersed twice in xylene for 5 min each. Finally, the sections were sealed with neutral resin and placed under a microscope for observation, and images were captured.

Statistical analysis

For comparisons between two groups, Student's *t* test was used to assess the significant of differences in normally distributed data. For comparisons of nonnormally distributed data, the Mann–Whitney *U* test was used. For comparisons involving more than two datasets, one-way ANOVA was conducted to assess the significance of differences. A *p* value < 0.05 was considered to indicate statistical significance. All statistical analysis were conducted using GraphPad Prism (version: 9.3.1) The data are presented as the mean ± standard deviation.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s43556-024-00193-z>.

Supplementary Material 1.

Acknowledgements

We would like to thank Shifeng Zhang, Liang Wang, Sen Huang, Xingyang Niu and Chi Xiao for their assistance.

Authors' contributions

Conceptualization: Zubiao Song, Weixi Zhang; Methodology: Zubiao Song, Qing Lin, Jiahui Liang; Writing-original draft preparation: Zubiao Song; Writing-review and editing: Qing Lin, Weixi Zhang; Funding Acquisition: Weixi Zhang; Resources: Weixi Zhang; Supervision: Weixi Zhang, Jiahui Liang. All authors have read and approved the final manuscript.

Funding

This study was supported by grants from the Natural Science Foundation of Guangdong Province (2021A1515010313), the Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases (2020B1212060017), Guangdong Provincial Clinical Research Center for Neurological Diseases (2020B1111170002), Southern China International Joint Research Center for Early Intervention and Functional Rehabilitation of Neurological Diseases (2015B050501003 and 2020A0505020004), Guangdong Provincial Engineering Center for Major Neurological Disease Treatment, Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease, Guangzhou Clinical Research and Translational Center for Major Neurological Diseases (201604020010).

Availability of data and materials

All data presented in this paper could be accessible through a material transfer agreement by contacting the corresponding author.

Declarations

Ethics approval and consent to participate

This study was approved by Institutional Animal Care and Use Committee of Sun Yat-Sen University (SYSU-IACUC-2023–001741). No human participants were involved in this study and informed consent was not applicable.

Consent for publication

Not applicable.

Competing interests

The authors have no conflicts to declare.

Received: 26 March 2024 Accepted: 1 July 2024

Published online: 09 August 2024

References

- Ro SH, Fay J, Cyuzuzo CI, Jang Y, Lee N, Song HS, et al. SESTRINs: emerging dynamic stress-sensors in metabolic and environmental health. *Front Cell Dev Biol.* 2020;8:603421. <https://doi.org/10.3389/fcell.2020.603421>.
- Chen Y, Huang T, Yu Z, Yu Q, Wang Y, Hu J, et al. The functions and roles of sestrins in regulating human diseases. *Cell Mol Biol Lett.* 2022;27(1):2. <https://doi.org/10.1186/s11658-021-00302-8>.
- Yang X, Xue P, Liu Z, Li W, Li C, Chen Z. SESN2 prevents the slow-to-fast myofiber shift in denervated atrophy via AMPK/PGC-1alpha pathway. *Cell Mol Biol Lett.* 2022;27(1):66. <https://doi.org/10.1186/s11658-022-00367-z>.
- Yang Y, Yang X, Huang Y, Liu S, Niu Y, Fu L. Resistance exercise alleviates dexamethasone-induced muscle atrophy via Sestrin2/MSTN pathway in C57BL/6J mice. *Exp Cell Res.* 2023;432(1):113779. <https://doi.org/10.1016/j.yexcr.2023.113779>.
- Relaix F, Zammit PS. Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. *Development.* 2012;139(16):2845–56. <https://doi.org/10.1242/dev.069088>.
- Rugowska A, Starosta A, Konieczny P. Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy. *Clin Epigenetics.* 2021;13(1):13. <https://doi.org/10.1186/s13148-021-01001-z>.
- von Maltzahn J, Jones AE, Parks RJ, Rudnicki MA. Pax7 is critical for the normal function of satellite cells in adult skeletal muscle. *Proc Natl Acad Sci U S A.* 2013;110(41):16474–9. <https://doi.org/10.1073/pnas.1307680110>.
- Sincennes MC, Brun CE, Lin AYT, Rosember T, Datzkiw D, Saber J, et al. Acetylation of PAX7 controls muscle stem cell self-renewal and differentiation potential in mice. *Nat Commun.* 2021;12(1):3253. <https://doi.org/10.1038/s41467-021-23577-z>.
- Fu X, Wang H, Hu P. Stem cell activation in skeletal muscle regeneration. *Cell Mol Life Sci.* 2015;72(9):1663–77. <https://doi.org/10.1007/s00018-014-1819-5>.
- Sin J, Andres AM, Taylor DJ, Weston T, Hiraumi Y, Stotland A, et al. Mitophagy is required for mitochondrial biogenesis and myogenic differentiation of C2C12 myoblasts. *Mol Basis Dis.* 2023;12(2):369–80. <https://doi.org/10.1080/15548627.2015.1115172>.
- Wang T, Hu W, Niu Y, Liu S, Fu L. Exercise improves lipid metabolism disorders induced by high-fat diet in a SESN2/JNK-independent manner. *Appl Physiol Nutr Metab.* 2021;46(11):1322–30. <https://doi.org/10.1139/apnm-2021-0241>.
- Liu S, Li H, Zhang Y, Song H, Fu L. Exercise ameliorates chronic inflammatory response induced by high-fat diet via Sestrin2 in an Nrf2-dependent manner. *Biochim Biophys Acta Mol Basis Dis.* 2023;1869(7):166792. <https://doi.org/10.1016/j.bbadis.2023.166792>.
- Li H, Liu S, Yuan H, Niu Y, Fu L. Sestrin 2 induces autophagy and attenuates insulin resistance by regulating AMPK signaling in C2C12 myotubes. *Exp Cell Res.* 2017;354(1):18–24. <https://doi.org/10.1016/j.yexcr.2017.03.023>.
- Puri PL, Sartorelli V. Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifications. *J Cell Physiol.* 2000;185(2):155–73. [https://doi.org/10.1002/1097-4652\(200011\)185:2%3c155::AID-JCP1%3e3.0.CO;2-Z](https://doi.org/10.1002/1097-4652(200011)185:2%3c155::AID-JCP1%3e3.0.CO;2-Z).

15. Ridgeway AG, Wilton S, Skerjanc IS. Myocyte enhancer factor 2C and myogenin up-regulate each other's expression and induce the development of skeletal muscle in P19 cells. *J Biol Chem*. 2000;275(1):41–6. <https://doi.org/10.1074/jbc.275.1.41>.
16. Braun T, Buschhausen-Denker G, Bober E, Tannich E, Arnold HH. A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. *EMBO J*. 1989;8(3):701–9. <https://doi.org/10.1002/j.1460-2075.1989.tb03429.x>.
17. Wright WE, Sassoon DA, Lin VK. Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. *Cell*. 1989;56(4):607–17. [https://doi.org/10.1016/0092-8674\(89\)90583-7](https://doi.org/10.1016/0092-8674(89)90583-7).
18. Perry RL, Rudnick MA. Molecular mechanisms regulating myogenic determination and differentiation. *Front Biosci*. 2000;5:D750–67. <https://doi.org/10.2741/perry>.
19. Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH, Jaenisch R. MyoD or Myf-5 is required for the formation of skeletal muscle. *Cell*. 1993;75(7):1351–9. [https://doi.org/10.1016/0092-8674\(93\)90621-v](https://doi.org/10.1016/0092-8674(93)90621-v).
20. Hernandez-Hernandez JM, Garcia-Gonzalez EG, Brun CE, Rudnicki MA. The myogenic regulatory factors, determinants of muscle development, cell identity and regeneration. *Semin Cell Dev Biol*. 2017;72:10–8. <https://doi.org/10.1016/j.semcdb.2017.11.010>.
21. Piochi LF, Machado IF, Palmeira CM, Rolo AP. Sestrin2 and mitochondrial quality control: potential impact in myogenic differentiation. *Ageing Res Rev*. 2021;67:101309. <https://doi.org/10.1016/j.arr.2021.101309>.
22. Wang H, Shi L, Liang T, Wang B, Wu W, Su G, et al. MiR-696 regulates C2C12 cell proliferation and differentiation by targeting CNTFRalpha. *Int J Biol Sci*. 2017;13(4):413–25. <https://doi.org/10.7150/ijbs.17508>.
23. Cheng X, Du J, Shen L, Tan Z, Jiang D, Jiang A, et al. MiR-204-5p regulates C2C12 myoblast differentiation by targeting MEF2C and ERRgamma. *Biomed Pharmacother*. 2018;101:528–35. <https://doi.org/10.1016/j.biopha.2018.02.096>.
24. Mohr AM, Mott JL. Overview of microRNA biology. *Semin Liver Dis*. 2015;35(1):3–11. <https://doi.org/10.1055/s-0034-1397344>.
25. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. *Nat Rev Dis Primers*. 2021;7(1):13. <https://doi.org/10.1038/s41572-021-00248-3>.
26. Ding Z, Lin J, Sun Y, Cong S, Liu S, Zhang Y, et al. miR-122-5p negatively regulates the transforming growth factor-beta/Smad signaling pathway in skeletal muscle myogenesis. *Cell Biochem Funct*. 2020;38(2):231–8. <https://doi.org/10.1002/cbf.3460>.
27. Xu D, Li S, Wang L, Jiang J, Zhao L, Huang X, et al. TAK1 inhibition improves myoblast differentiation and alleviates fibrosis in a mouse model of Duchenne muscular dystrophy. *J Cachexia Sarcopenia Muscle*. 2021;12(1):192–208. <https://doi.org/10.1002/jcsm.12650>.
28. Yamamoto M, Legendre NP, Biswas AA, Lawton A, Yamamoto S, Tajbakhsh S, et al. Loss of MyoD and Myf5 in skeletal muscle stem cells results in altered myogenic programming and failed regeneration. *Stem Cell Reports*. 2018;10(3):956–69. <https://doi.org/10.1016/j.stemcr.2018.01.027>.
29. Brearley MC, Li C, Daniel Z, Loughna PT, Parr T, Brameld JM. Changes in expression of serine biosynthesis and integrated stress response genes during myogenic differentiation of C2C12 cells. *Biochem Biophys Res*. 2019;20:100694. <https://doi.org/10.1016/j.bbrep.2019.100694>.
30. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. *J Pathol*. 2010;221(1):3–12. <https://doi.org/10.1002/path.2697>.
31. Guiraud S, Davies KE. Regenerative biomarkers for Duchenne muscular dystrophy. *Neural Regen Res*. 2019;14(8):1317–20. <https://doi.org/10.4103/1673-5374.253534>.
32. Faralli H, Dilworth FJ. Turning on myogenin in muscle: a paradigm for understanding mechanisms of tissue-specific gene expression. *Comp Funct Genomics*. 2012;2012:836374. <https://doi.org/10.1155/2012/836374>.
33. Murach KA, White SH, Wen Y, Ho A, Dupont-Versteegden EE, McCarthy JJ, et al. Differential requirement for satellite cells during overload-induced muscle hypertrophy in growing versus mature mice. *Skelet Muscle*. 2017;7(1):14. <https://doi.org/10.1186/s13395-017-0132-z>.
34. Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. *Physiol Rev*. 2011;91(4):1447–531. <https://doi.org/10.1152/physrev.00031.2010>.
35. Stuart CA, Stone WL, Howell ME, Brannon MF, Hall HK, Gibson AL, et al. Myosin content of individual human muscle fibers isolated by laser capture microdissection. *Am J Physiol Cell Physiol*. 2016;310(5):C381–9. <https://doi.org/10.1152/ajpcell.00317.2015>.
36. Talbot J, Maves L. Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for susceptibility and resistance to muscle disease. *Wiley Interdiscip Rev Dev Biol*. 2016;5(4):518–34. <https://doi.org/10.1002/wdev.230>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.